 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
- KB174 / Kaleido
[VIRTUAL] COMMUNITY SHIFT IN THE GUT MICROBIOME IS A POTENTIAL MECHANISM FOR REDUCTION IN GUT MICROBIOTA-ASSOCIATED AMMONIA BY THE NOVEL SYNTHETIC GLYCAN, KB174, IN PATIENTS WITH WELL-COMPENSATED CIRRHOSIS () - Oct 11, 2020 - Abstract #AASLD2020AASLD_610;
It also supports the proposed mechanism that KB174 reduced gut associated ammonia through specifically modulating the microbiome composition, likely by promoting Parabacteroides, a core commensal taxa known to ferment glycans to propionate as the primary fermentation end-product, which in turn outcompetes ammonia-producing bacteria. Future work is expected to focus on patients with cirrhosis who exhibit psychomotor function abnormalities consistent with hepatic encephalopathy.
- Xifaxan (rifaximin) / Alfa Wassermann, Bausch Health, Norgine, ASKA
[VIRTUAL] KB174 reduces relative abundance of multidrug resistance (MDR) enterobacteriaceae in fecal samples from patients with cirrhosis in an ex vivo test system (Poster Area) - May 30, 2020 - Abstract #EASLILCI2020EASL-ILC-I-1551;
P=N/A
KB174 reduces the relative abundance of pathobionts in fecal samples from patients with cirrhosis. Based on these results, KB174 was investigated in a clinical study in cirrhotic patients (NCT03855956).
- KB174 / Kaleido
[VIRTUAL] A randomized, double-blind study to evaluate the safety and tolerability of KB174, a novel synthetic glycan, in patients with well-compensated cirrhosis (Poster Area) - May 30, 2020 - Abstract #EASLILCI2020EASL-ILC-I-1508;
This is the first clinical study to report the effect of KB174 in patients with cirrhosis. KB174 titrated up to 72g was shown to be well tolerated with no clinically significant safety signals observed in patients with well-compensated cirrhosis.
- ||| KB174 / Kaleido Biosci
Trial completion, Trial completion date: Clinical Food Study to Evaluate the Effect of KB174 on the Gut Microbiome in Subjects With Well-compensated Cirrhosis (clinicaltrials.gov) - May 14, 2020
P=N/A, N=40, Completed, Sponsor: Kaleido Biosciences
KB174 titrated up to 72g was shown to be well tolerated with no clinically significant safety signals observed in patients with well-compensated cirrhosis. Recruiting --> Completed | Trial completion date: Feb 2020 --> Oct 2019
- Xifaxan (rifaximin) / Alfa Wassermann, Bausch Health, Norgine, ASKA
KB174 REDUCES RELATIVE ABUNDANCE OF MULTIDRUG RESISTANT (MDR) ENTEROBACTERIACEAE IN FECAL SAMPLES FROM PATIENTS WITH CIRRHOSIS IN AN EX VIVO TEST SYSTEM () - May 4, 2020 - Abstract #DDW2020DDW_5613;
P=N/A
KB174 reduces the relative abundance of pathobionts in fecal samples from patients with cirrhosis. Based on these results, KB174 was investigated in a clinical study in cirrhotic patients (NCT03855956)
- KB174 / Kaleido
A RANDOMIZED, DOUBLE-BLIND STUDY TO EVALUATE THE SAFETY AND TOLERABILITY OF KB174, A NOVEL SYNTHETIC GLYCAN, IN PATIENTS WITH WELL-COMPENSATED CIRRHOSIS () - May 4, 2020 - Abstract #DDW2020DDW_5600;
This is the first clinical study to report the effect of KB174 in patients with cirrhosis. KB174 titrated up to 72g was shown to be well tolerated with no clinically significant safety signals observed in patients with well-compensated cirrhosis
- ||| KB174 / Kaleido Biosci
Enrollment open: Clinical Food Study to Evaluate the Effect of KB174 on the Gut Microbiome in Subjects With Well-compensated Cirrhosis (clinicaltrials.gov) - Mar 15, 2019
P=N/A, N=36, Recruiting, Sponsor: Kaleido Biosciences
KB174 titrated up to 72g was shown to be well tolerated with no clinically significant safety signals observed in patients with well-compensated cirrhosis Not yet recruiting --> Recruiting
- ||| KB174 / Kaleido Biosci
New trial: Clinical Food Study to Evaluate the Effect of KB174 on the Gut Microbiome in Subjects With Well-compensated Cirrhosis (clinicaltrials.gov) - Feb 27, 2019
P=N/A, N=36, Not yet recruiting, Sponsor: Kaleido Biosciences